Benign Tumors
Also known as: Benign neoplasms, Noncancerous tumors, Neoplasia, Growth, Neoplasm
Methodology & AI Transparency ⓘ
Benign Tumors Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Tumors are abnormal growths in your body.
- 2 Real-world patient consensus: Synonyms for Benign Tumors (D36.9): Benign neoplasms, Noncancerous tumors, Neoplasia (Cancer & Oncology).
- 3 Typical cash cost range: Differential triage of Benign Tumors (D36.9) utilizes multidisciplinary tumor-board planning in Benign Tumors (D36.9: (surgery).
- 4 Top reported side effects / signs: Objective lab/clinical target for Benign Tumors: Pathology / Molecular in Benign Tumors (D36.9: Genomic Staging) (Guideline-concordant surveillance (D36.9)) and Complete Blood Count in Benign Tumors (D36.9: (ANC, Hemoglobin, Platelets)).
Ask our AI Specialists anything about Benign Tumors
What Is Benign Tumors?
Tumors are abnormal growths in your body. They can be either benign or malignant. Benign tumors aren't cancer. Malignant ones are. Benign tumors grow only in one place. They cannot spread or invade other parts of your body. Even so, they can be dangerous if they press on vital organs, such as your brain. Tumors are made up of extra cells. Normally, cells grow and divide to form new cells as your body needs them. When cells grow old, they die, and new cells take their place. Sometimes, this process goes wrong. New cells form when your body does not need them, and old cells do not die when they should. These extra cells can divide without stopping and may form a tumor.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Benign Tumors (ICD-10 D36.9) is driven by angiogenesis [Benign Tumors D36.9]; Cross-referenced with NIH MeSH (Papilloma, Fibroma), specialists in Cancer, Oncology & Supportive Care monitor Complete Blood Count in Benign Tumors (D36.9: (ANC, Hemoglobin, Platelets)) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Presentation of Benign Tumors (D36.9): abnormality detected early in Benign Tumors (D36.9: on age-appropriate screening)
- • Secondary Benign Tumors clinical sign: persistent painless lump, in Benign Tumors (D36.9: non-healing ulcer/mole change,)
- • Symptom flares in Benign Tumors correlating with Pathology / Molecular in Benign Tumors (D36.9: Genomic Staging) deviation outside Guideline-concordant surveillance (D36.9)
- • Functional cancer & oncology impact requiring multidisciplinary tumor-board planning in Benign Tumors (D36.9: (surgery) evaluation (D36.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Benign Tumors Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | D36.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Pathology / Molecular in Benign Tumors (D36.9: Genomic Staging) | Guideline-concordant surveillance (D36.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Benign Tumors (D36.9: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (D36.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Benign Tumors (D36.9: Organ Function Panel) | Preserved renal/hepatic clearance (D36.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Benign Tumors
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Dutasteride and Tamsulosin Hydrochloride Jalyn • RxCUI 996097 | 5-alpha Reductase Inhibitor | 85% | $1.8643 | $ 84.00 /mo |
| 68ga-Dotatate Netspot • RxCUI RXN-69488001-1794 | FDA Prescription Therapeutic Agent | 93% | $1.3200 | $ 61.96 /mo |
| Terazosin Hydrochloride Hytrin • RxCUI 260376 | alpha-Adrenergic Blocker | 78% | $0.1246 | $ 7.45 /mo |
| Tezruly (Terazosin) Tezruly • RxCUI 260376-B70954592 | alpha-Adrenergic Blocker | 76% | $0.1246 | $ 17.47 /mo |
| Alfuzosin Hydrochloride Alfuzosin Hydrochloride Generic • RxCUI 861132 | alpha-Adrenergic Blocker | 75% | $0.1047 | $ 12.74 /mo |
| Lomustine Gleostine • RxCUI 197894 | Alkylating Drug | 83% | $0.5700 | $ 31.58 /mo |
| Doxazosin Cardura • RxCUI 197626 | alpha-Adrenergic Blocker | 81% | $0.0580 | $ 5.74 /mo |
| Nirogacestat Ogsiveo • RxCUI 2680360 | Gamma Secretase Inhibitor | 89% | $0.7600 | $ 39.28 /mo |
| Tamsulosin Hydrochloride Flomax • RxCUI 863669 | alpha-Adrenergic Blocker | 90% | $0.0515 | $ 6.01 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Benign Tumors)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Baseline Total Testosterone Level on Successful Treatment of Sexual Dysfunction: What a 1,075-Participant Study Found Low TT levels at baseline did not negatively influence response to tadalafil in men of advancing age with concomitant lower urinary tract symptoms and benign prostatic hyperplasia and erectile dysfunction. The journal of sexual medicine • 2016-05-15 • Randomized Controlled Trial | N = 1,075 | 96/100 | PMID 27017071 ↗ |
| New Insights on Development and validation of a multivariable prognostic model in de novo: What a 1,058-Participant Study Found A prognostic model for men with de novo mCSPC was developed and validated in an independent testing set. Prostate cancer and prostatic diseases • 2023-03-15 • Phase III Randomized Trial | N = 1,058 | 96/100 | PMID 35790787 ↗ |
| New Insights on Benefits and safety of Combination Comprising Tamsulosin and PDE5-Is, Relative to: What a 1,144-Participant Study Found However, therapy discontinuation due to pain and AEs did not increase with increase in AEs. American journal of men's health • 2020-01-15 • Meta-Analysis | N = 1,144 | 94/100 | PMID 33342335 ↗ |
| New Insights on Monotherapies and Combination Therapy of Tamsulosin and Tadalafil for Treating: What a 1,531-Participant Study Found Tadalafil combined with tamsulosin was more effective in the treatment of male LUTS/BPH, with or without ED, on the improvement of total IPSS, QoL, and Qmax. Urologia internationalis • 2024-01-15 • Meta-Analysis | N = 1,531 | 94/100 | PMID 38081154 ↗ |
| New Insights on Tadalafil on nighttime voiding (nocturia) in men with lower urinary tract: What a 752-Participant Study Found A statistically significant improvement in nocturnal frequency was seen with tadalafil over placebo; however, the treatment difference was small and not considered clinically meaningful. World journal of urology • 2014-10-15 • Randomized Controlled Trial | N = 752 | 93/100 | PMID 24504761 ↗ |
Benign Tumors Patient Community & “People Like Me” Threads
Filter Benign Tumors community threads and patient logs by age, biological sex, dosage, and treatment duration.